Progressive supranuclear palsy treatment market
Progressive Supranuclear Palsy Treatment Market, by Drug Type (Dopamine, Anticholinergic Agents, Tricyclic Antidepressants, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
- Nov 2020
- CMI4277
- 195 Pages
- Excel & Pdf
- Pharmaceutical
Progressive supranuclear palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech, and swallowing. It is caused due to increasing numbers of brain cells getting damaged over time. Progressive supranuclear palsy (PSP) is also known as Steele-Richardson-Olszewski syndrome. Increasing incidence of progressive supranuclear palsy (PSP) is expected to boost the market. For instance, according to the Chicago Dizziness and Hearing, an article published in August 2020 reports that worldwide progressive supranuclear palsy is estimated to affect about 4-6.4/100,000 persons and the incident rate for new cases for ages 50-99 is estimated to be 5.3/100,000, and the crude incidence rate is 1.1/100,000.
The global progressive supranuclear palsy treatment market is estimated to be valued at US$ 14.38 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).
Figure 1. Global Progressive Supranuclear Palsy Treatment Market Share (%), by Region, 2020
The increasing product development and ongoing trials is expected to propel growth of the global progressive supranuclear palsy treatment market
Major players in the market are focused on drug development for progressive supranuclear palsy treatment, which is expected to boost the market growth over the forecast period. For instance, in September 2020, Alzprotect announced the recruitment of the first five patients to be participated in its Phase IIa clinical trial with its drug candidate AZP2006 (EZEPROGIND) for progressive supranuclear palsy (PSP) treatment. PSP is an orphan disease and moreover the company received an orphan drug designation by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).
However, failure of drug results in the clinical trial is expected to hinder the market growth over the forecast period. For instance, in July 2019, AbbVie, a biopharmaceutical company halted its Phase 2 trial of its anti-tau antibody ABBV-8E12 for progressive supranuclear palsy. The trial was stopped due to failure in futility analysis.
Progressive Supranuclear Palsy Treatment Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 14.38 Mn |
| Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 5.3% | 2027 Value Projection: | US$ 20.68 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2. Global Progressive Supranuclear Palsy Treatment Market Share (%), by Drug Type, 2020
Increasing incidence of progressive supranuclear palsy in North America is expected to boost the market growth
North America is expected to hold dominant position in the global progressive supranuclear palsy treatment market, owing to increasing new cases of progressive supranuclear palsy in this region. For instance, according to the National Organization for Rare Disorders (NORD), an article published in 2017, report that progressive supranuclear palsy (PSP affects around 20,000 people in the U.S. each year. The study also states that PSP may affect as many as 5 in 100,000 people and males are affected more often than females.
Global Progressive Supranuclear Palsy Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global progressive supranuclear palsy treatment drugs market during the forecast period.
Key Players
Major players operating in the global progressive supranuclear palsy treatment market include AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Reimbursement Scenario
- Epidemiology
- Pest Analysis
- Regulatory Scenario
- New Product Launches
- Collaborations and Agreements
- Market Trends
- Market Dynamics
- Global Progressive Supranuclear Palsy Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Market Scenario
- Impact of COVID-19 Market on the Progressive Supranuclear Palsy Treatment Products
- Global Progressive Supranuclear Palsy Treatment Market, By Drug Type, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Dopamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Anticholinergic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Tricyclic Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Progressive Supranuclear Palsy Treatment Market, By Region, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Acorda Therapeutics Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Biogen Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol-Myers Squibb Co.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- UCB Biopharma
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AlzProtect
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Asceneuron Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- TauRx Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline PLC
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 40 market data tables and 35 figures on "Progressive Supranuclear Palsy Treatment Market” - Global forecast to 2027